Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. CRWV
8. CME
9. ADBE
10. HUMA

Go back to Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

July 27, 2021 7:35 AM EDT

NEW YORK, July 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel... More